Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 8/20 | 1.00 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 1.00 |
| ▸ | LPAR4 | Q99677 | 3/20 | 1.00 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 1.00 |
| ▸ | LPAR6 | P43657 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.85 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.68 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.68 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.68 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362553 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8508094 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL13043253 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL2935599 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL2936577 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8508530 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8509455 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8736955 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8509038 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8507661 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064521-A | Method for identifying organic phosphate and application thereof | 中山大学 | 2025-05-30 | — | — | CN | claimed |
| CN-118178324-B | FAP alpha hydrolysis charge-turned liposome and composition, and preparation method and application thereof | 锐康九域(厦门)医药科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-120064521-A | Method for identifying organic phosphate and application thereof | 中山大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | disclosed |
| US-20250037787-A1 | CONCENTRATION BOUNDS IN LARGE NETWORKS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | US | disclosed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | disclosed |
| US-20170254822-A1 | METHODS AND KITS FOR DETECTING AND DIAGNOSING NEUROTRAUMA | APOLLO ENDOSURGERY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170254822-A1 | METHODS AND KITS FOR DETECTING AND DIAGNOSING NEUROTRAUMA | APOLLO ENDOSURGERY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170114125-A1 | METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | APOLLO ENDOSURGERY INTERNATIONAL, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170114125-A1 | METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | APOLLO ENDOSURGERY INTERNATIONAL, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170088634-A1 | TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | APOLLO ENDOSURGERY, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20080145360-A1 | Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2008-06-19 | — | — | US | disclosed |
| US-20080138334-A1 | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same | SABBADINI ROGER A | 2008-06-12 | — | — | US | disclosed |
| US-20080138334-A1 | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same | SABBADINI ROGER A | 2008-06-12 | — | — | US | disclosed |
| US-20080090303-A1 | Methods and Reagents for Detecting Bioactive Lipids | APOLLO ENDOSURGERY, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090303-A1 | Methods and Reagents for Detecting Bioactive Lipids | APOLLO ENDOSURGERY, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20070281320-A1 | Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2007-12-06 | — | — | US | disclosed |
| US-20070280933-A1 | Methods for decreasing immune response and treating immune conditions | APOLLO ENDOSURGERY, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070148168-A1 | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | LPATH, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070148168-A1 | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | LPATH, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280933-A1 | Methods for decreasing immune response and treating immune conditions | LPAR1, LPAR2, S1PR1 | LPAR1 1/4885ENPP2 19/4885LPAR3 10/4885 |
| US-20170114125-A1 | METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | LPAR5, LPAR2, LPAR6 | LPAR1 5/4885ENPP2 9/4885LPAR3 6/4885 |
| US-20080145360-A1 | Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders | CD47, SGMS1, ALG1 | LPAR1 5/4885ENPP2 67/4885LPAR3 11/4885 |
| US-20170088634-A1 | TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | LPAR4, LPAR5, LPAR1 | LPAR1 3/4885ENPP2 47/4885LPAR3 7/4885 |
| US-20070281320-A1 | Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same | SGMS1, SGMS2, LPAR1 | LPAR1 3/4885ENPP2 93/4885LPAR3 7/4885 |
| US-20080138334-A1 | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same | CD47, ALG1, SGMS1 | LPAR1 4/4885ENPP2 73/4885LPAR3 7/4885 |
| US-20070148168-A1 | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions | S1PR1, S1PR5, S1PR3 | LPAR1 9/4885ENPP2 21/4885LPAR3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.